Integra Lifesciences (IART) SVP granted 15,957 RSUs with 1,147 shares withheld for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
INTEGRA LIFESCIENCES HOLDINGS CORP senior vice president and principal accounting officer Jeffrey Mosebrook received a grant of 15,957 restricted stock units on March 11, 2026. These RSUs will vest 33% on the first and second anniversaries of the grant date and 34% on the third anniversary.
To cover tax liabilities, 341 common shares at $9.55 per share on March 10, 2026 and 806 common shares at $9.61 per share on March 11, 2026 were withheld. Following these transactions, Mosebrook directly owns 35,453 common shares and holds 15,957 RSUs.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Mosebrook Jeffrey
Role
SVP, Fin & Princ Acct Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 15,957 | $0.00 | -- |
| Tax Withholding | Common Stock | 806 | $9.61 | $8K |
| Tax Withholding | Common Stock | 341 | $9.55 | $3K |
Holdings After Transaction:
Restricted Stock Units — 15,957 shares (Direct);
Common Stock — 35,453 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did INTEGRA LIFESCIENCES (IART) executive Jeffrey Mosebrook report on this Form 4?
Jeffrey Mosebrook reported receiving 15,957 restricted stock units and having 1,147 common shares withheld for taxes. The RSU grant increases his equity-based compensation, while the tax-related share withholdings are routine and not open-market sales.
How many restricted stock units did Jeffrey Mosebrook receive from INTEGRA LIFESCIENCES (IART)?
He received a grant of 15,957 restricted stock units. These RSUs convert into common stock as they vest and represent additional long-term equity compensation tied to his continued service and the company’s performance over the vesting period.
What is the vesting schedule for Jeffrey Mosebrook’s 15,957 RSUs at INTEGRA LIFESCIENCES (IART)?
The 15,957 RSUs vest 33% on the first anniversary, 33% on the second, and 34% on the third anniversary of the March 11, 2026 grant date. This three-year schedule encourages retention and aligns compensation with long-term company results.
Were Jeffrey Mosebrook’s INTEGRA LIFESCIENCES (IART) transactions open-market sales?
No, the 341 and 806 common shares involved were withheld to satisfy tax liabilities. These “F” code transactions are tax-withholding dispositions by the issuer, not discretionary open-market sales, and are common when stock awards vest or are granted.